Analyst Research Report Snapshot


Venus Remedies Limited (VENUSREM) - Financial Analysis Review






06 Jan 2014





Companies referenced:


Available for Immediate Download

Venus Remedies Limited (VENUSREM) - Financial Analysis Review Summary Venus Remedies Limited (Venus) is a pharmaceutical company. The company develops, manufactures and commercializes pharmaceutical products. Venus’s products include Mebatic, Zydotum, Supime, Pirotum, and Neurotol. Its products are used in the treatment of anaerobes, aerobes and protozoa, the causative microorganisms for gastrointestinal infections such as acute watery diarrhea, dysentery, enteritis, entero colitis, traveler's diarrhea and acute food poisoning, among others. GlobalData's Venus Remedies Limited (VENUSREM) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Venus Remedies Limited Key Recent Developments: Aug 05, 2013: Venus Remedies Gets GLP Accreditation For Its R&D Center Jul 18, 2013: PIC/S GMP FOR ALL 9 UNITS OF VENUS REMEDIES May 18, 2013: Venus Remedies Reports Revenue Of INR4.6 Billion In Fiscal 2013 Mar 25, 2013: Venus Remedies Launches Anti-Stress Herbal Product, Ezenus Feb 14, 2013: Venus Remedies Receives Australian GMP From TGA For Four Facilities This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.